QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Corvus PharmaceuticalsAnixa BiosciencesPhaseBio PharmaceuticalsMarker TherapeuticsMoleculin Biotech
SymbolNASDAQ:CRVSNASDAQ:ANIXNASDAQ:PHASNASDAQ:MRKRNASDAQ:MBRX
Price Information
Current Price$3.24$4.95$3.81$2.50$4.29
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.81.41.61.11.2
Analysis Score3.33.53.53.33.5
Community Score2.52.52.32.42.7
Dividend Score0.00.00.00.00.0
Ownership Score3.30.81.70.00.0
Earnings & Valuation Score0.00.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$8.00$8.50$13.00$8.50$15.00
% Upside from Price Target146.91% upside71.72% upside241.21% upside240.00% upside249.65% upside
Trade Information
Market Cap$90.92 million$129.08 million$111.88 million$120.06 million$112.74 million
Beta1.811.581.851.272.11
Average Volume1,117,996369,647338,752661,5723,413,008
Sales & Book Value
Annual RevenueN/A$250,000.00$2.36 million$210,000.00N/A
Price / SalesN/A516.3247.41571.73N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.42 per share$0.35 per share$2.09 per share$0.96 per share$0.34 per share
Price / BookN/A14.141.822.60N/A
Profitability
Net Income$-46,670,000.00$-10,020,000.00$-39,250,000.00$-21,430,000.00$-13,200,000.00
EPS($1.59)($0.59)($1.43)($0.47)($0.32)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-79.15%-153.08%-220.57%-68.00%-113.25%
Return on Assets (ROA)-63.99%-129.89%-110.30%-54.26%-63.20%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A1.87%N/AN/A
Current Ratio4.38%7.88%4.39%5.03%4.44%
Quick Ratio4.38%7.88%4.39%5.03%4.44%
Ownership Information
Institutional Ownership Percentage60.80%7.68%58.58%29.42%4.82%
Insider Ownership Percentage45.12%23.30%17.00%30.90%8.30%
Miscellaneous
Employees523502811
Shares Outstanding28.06 million26.08 million29.37 million48.03 million26.28 million
Next Earnings Date3/4/2021 (Estimated)3/8/2021 (Estimated)3/29/2021 (Estimated)3/11/2021 (Estimated)3/18/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.